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In radiotherapy center, the waiting time represents one of the
most greater problems. The principal cause of this phenomenon
is represented by a smaller offer in comparison to the demand.
In fact, in these last years the application of radiotherapy is
increased both for the most greater incidence of new cases of can-
cer and for a greater extension in the radiotherapy indications. The
delay in the beginning of the radiant treatment has on the patient
negative effects is direct (what the tumoral growth, the worsening
of the symptoms, the psychological effects) both indirect effects
like trips of the hope and pressure on the radiation oncologist, that
can jeopardize the quality of the same radiant treatment. Numer-
ous evidences have shown that the delay in to begin can influence
the obtainable results with the radiotherapy, allowing the prolifer-
ation of clonogenic cells inside the target and consequently a dim-
inution of the local control. Besides the delay in the beginning of
the radiotherapy can influence negatively the process of onset of
the metastasis. None of the numerous present evidences in litera-
ture on the influence of the delay of the radiotherapy and that they
suggest the role of the delay of the radiotherapy in the increase of
the risk of local relapse, it reaches the level of ‘evidence-based
medicine’. In fact anybody study show a clear relationship among
cause and effect, besides none of these studies has been drawn to
the purpose to verify if this relationship exists. It is reasonable
however to think that, through the improvements reached in the
knowledge of the tumoral progression in the patients waiting for
radiotherapy, especially as it regards the patients affections from
the head and the neck cancer, the delay of the I begin some radio-
therapy is responsible of many local failures. Although the effects
of the delay of the radiotherapy is not the same for all the tumors,
the negative effects tied up to it, can frustrate the benefits effects
reached by the technological advancements of the radiotherapy.
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Until now, the majority of the cancer therapy have not been
specific: not based on the tumour biology and associated to a
meaningful toxicity. The classical radiobiology has furnished
valid elements on the cellular kinetics, has furnished valid ele-
ments on the cellular kinetics, on the processes of reparation
and damage of the DNA and on the biological basis of administra-
tion of the dose, putting the bases for the new radiobiology,
regarding the interactions of radiation ionizing and molecular-
targeted agents. In the last years the therapeutic approach to
the tumour is changed: the target of the cancer therapies is not
more directly the neoplastic cells but is directed against targets
necessary for tumour cell growth and viability with little toxicity
to normal cells compared to conventional cytotoxic agents (Fig. 1).
Moreover, the modern radiobiology it is turned toward the
molecular biology, not more the DNA as target but not DNA tar-
gets: specific growth factor or signal transduction inhibitors, as
CDK, PKC, EGFR, VEGF, FT, MAPK. The non-DNA targets they
result effective in to determine the cellular death or to make
the most sensitive cells to the radiations. In 2006, Bunn1 reported
that ‘Targeted therapy and radiation may work together in two
Fig. 1. The combination of targeted therapy and radiother-
apy to treat cancer (Giaccia A. ASTRO 2007).
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ways, by increasing effectiveness of radiotherapy in local tumour
and also a systemic effect by killing cancer cells outside the
tumour site as well. . .. First, that novel (targeted therapy) agents
in themselves do not cure the cancer, but, we have also learned
that while these novel agents alone do not cure advanced cancer,
they may have the ability to cure patients when combined with
radiation or chemotherapy in earlier cancers. The epidermal
growth factor receptor (EGFR), a member of the HER (erbB) family
of transmembrane receptor tyrosine kinases, is overexpressed in
the majority of solid tumours as non-small-cell lung cancers
(NSCLC) or squamous cell carcinoma of the head and neck
(SCCHN). EGFR may also play a role in cellular responses to che-
motherapy or radiotherapy. The expression of EGFR and its
ligands is upregulated by cells in response to irradiation, and
the ability of cells to continue dividing and resist radiation-
induced damage appears to be influenced by activation of the
EGFR signaling pathway.2,3
An advantage of the combination among target therapy and
radiotherapy it is that they each affect the cell growth cycle at
different point. Chinnaiyan et al.4 reported that radiation most
commonly induces an arrest at the G2 point, while Erlotinib
more strongly affects the G1 point resulting in an increase of
the radiotherapy-induced apoptosis. In the phase III trial of
Bonner et al.5 the addition of Cetuximab to high-dose radiation
for curative intent in patients with squamous cell carcinoma of
the head and neck increased three-year survival from 45% to
55% (P = 0.03). The EGFR-targeted therapies and radiation fur-
ther to arrest cell cycle progression at different checkpoints,
when administered in combination produce enhanced antipro-
liferative activity, apoptosis induction, inhibition of DNA dam-
age repair, and antiangiogenic and antimetastatic effects.4,6–9
Data presented by Azria et al.10 suggest that tumour radia-
tion-sensitization through the inhibition of EGFR signaling
could yield a therapeutic gain by increasing the locoregional
control rate in patients with EGFR-overexpressing rectal cancer.
With regard the relationship between radiation and antiangio-
genic agents, the concept that attacking a tumour’s supportive
blood vessel network could offer a means of improving cancer
cure rates has received a great deal of attention in recent years.
Initially tumour growth depends upon its host for its blood sup-
ply.3 But for growing beyond a certain size, angiogenesis is
required (Fig. 2). The combination may produce a synergistic
anti-tumour effect. The agents are divided, mainly, in two
groups: (1) VEGF inhibitors (as the Semaxanib, used for
advanced malignancies) and (2) Anti-VEGF and VEGFR Antibod-
ies (as the Bevacizumab).
Enhancement of tumour response to radiation plus antiangio-
genic agents has also been explained by an increase in tumour
oxygenation after treatment. Indeed the application of vascular
targeting strategies as adjuvants to standard therapeutic modali-
ties may offers unique opportunities to develop even more effec-
tive cancer therapies. The non-DNA targets they result effective
in to determine the cellular death or to make the most sensitive
cells to the radiations. In conclusion, an only mechanism that
conducts to the radiation sensitizing does not exist.
The mechanism of radioresistance or radiosensitization is
complex and understanding different factors like the induction
of apoptosis, effects on the regulation of the cellular cycle, the
reparation of the DNA and the angiogenesis. Bentzen et al.,
unpublished data in 2005, have hypothesized that besides the
steel paradigm other types of interactions exist, what biological
cooperation, kinetic cooperation and normal tissue protection.
The future directions of the radiobiology it is the use of therapeu-
tic strategies that integrate the ionizing radiation in combination
with one or more molecular-targeted agents There is immense
potential for improving efficacy and diminishing toxicity through
application of target therapy combined with radiations or chemo-
radiations. The future of cancer treatment is targeted therapy,
and as brought from by Pegram et al.11 ‘Targeted therapy: Wave of
the future’. The purpose of the new treatments strategies and
new drug to convert cancer into a chronic disease.
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